Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia

Phase: PHASE1 | Sponsor: NYU Langone Health | Compound: Psilocybin

Status

planned

Institution

NYU Langone Health

Start date

2026-07-01

End date

2030-09-30

Registry ID

NCT07607938

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.